semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Acute Heart Failure Age ≥ 18 years 2. Patients with acute heart failure with associated signs or symptoms (dyspnea on exertion, orthopnea, paroxysmal dyspnea, peripheral oedema, chest x-ray with pulmonary congestion) 3. Serum levels of NT-proBNP ≥ 1000 pg/ml within 48 hours of Informed Consent 4. Written informed consent prior to study participation  Type 1 diabetes 2. Participants of child-bearing age without adequate contraception 3. Pregnancy or lactating females 4. Cardiogenic shock 5. Acute coronary syndrome within 30 days prior to randomization 6. Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization 7. Signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (pH ≤ 7.30 and glucose >14 mmol/l and HCO3 ≤ 18 mmol/l) 8. Signs of uncontrolled active infection 9. Dyspnea due to non-cardiac causes (severe pulmonary disease, anemia, severe obesity), non-HF causes such as acute or chronic respiratory disorders 10. Coronary artery disease with requirement for revascularization within the study period 11. Renal impairment (GFR < 20 ml/min/1,73 m2) 12. Known hepatic impairment (as evidenced by total bilirubin >3 mg/dL) or history of cirrhosis with evidence of portal hypertension (e.g., presence of esophageal varices) 13. Uncontrolled thyroid disease 14. Endocrinopathies like Graves' disease, acromegaly, Cushings' disease 15. Hypertensive retinopathy or encephalopathy 16. Bariatric surgery in last 2 years prior to randomization 17. Patients in whom study participation is not deemed appropriate under consideration of clinical wellbeing by the principal investigator 18. The subject is mentally or legally incapacitated 19. The subject received an investigational drug within 30 days prior to into this study 20. Urinary tract infections or significant formation of residual urine in medical history 21. Patients with particular risk for ketoacidosis (alcohol abuse, pancreatitis, pancreatic insulin deficiency from any cause, caloric restriction etc.) or ketoacidosis in the past 22. Frequent hypoglycaemic events (in the opinion of the investigator) 23. Intolerance to Empagliflozin and excipients in Empagliflozin or rather placebo 24. Patients with severe stenosis or regurgitation of the aortic, pulmonary or mitral valve
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease Dyspnea severe COPD (post bronchodilator FEV1/FVC < 70% and FEV1 < 50% predicted) stable clinical condition(no exacerbation in the 4 weeks prior to study participation with no change in medications) dyspnea as a main symptom that limited daily activities  obvious pulmonary bullae demonstrated by chest CT scan or X-ray examination facial trauma/malformation; recent facial, upper airway or upper gastrointestinal tract surgery systolic blood pressure > 160mmHg or diastolic blood pressure > 100mmHg at rest unstable angina or a myocardial infarct in the previous four weeks resting sinus tachycardia ( > 120 beats/min) patients with musculoskeletal or neurological disorders patients who are unable to give informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-29.0,  Type1diabetes Type 1 diabetes
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Sleep Apnea, Obstructive Diabetes Mellitus, Type 1 Type 1 diabetes patients with a diabetes duration of at least 5 years Age between 18 and 60 years old  OSAS treated with CPAP Chronic alcoholism Neuromuscular disease Drugs interfering with sinus variability (betablockers, antiarrhythmics, ivabradine), presence of pacemaker Pregant woman
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 1 Diabetes >18 years type 1 diabetes had been treated with insulin pump for more than three months had hypoglycemia unawareness with a hypoglycemia perception threshold below 60 mg/dL and/or had had at least one severe hypoglycemia event in the previous year  > 18 years any serious disease that could interfere with the study pregnancy incompatibility with monitoring irregular management of diabetes hearing loss and low vision preventing them from using the devices
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Copd Dyspnea Lung Diseases a diagnosis of COPD Dyspnea in daily living (2-4 on the modified medical research council dyspnea scale) Clinically stable  exercise contraindication Any musculoskeletal problems, cardiovascular or neurological comorbidities that limits exercise exacerbation during the study Inability to chew or patients with swallowing disorders
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Diabetes Mellitus, Type 1 Children and adolescent suffering from type 1 Diabetes Mellitus, for at least 3 years from the onset of the disease  Children with Congenital Heart Diseases Children with acquired cardiac diseases Children with other systemic diseases Symptomatic diabetic cardiomyopathy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  PreDiabetes Prediabetes: Participants must have a diagnosis of prediabetes within the last 2 years or meet for prediabetes. The American Diabetes Association guidelines defines prediabetes as Fasting Plasma Glucose (FPG) 100-125 mg/dl, 2h glucose 140-199 mg/dl after Oral Glucose Tolerance Test (OGTT), or hemoglobin A1c (HbA1c) approximately 5.7-6.4% Comorbidities: Participants must have a history of comorbid diagnosis such as hypertension and/or hyperlipidemia to participate in the behavioral portion of this study. Hypertension is defined as blood pressure greater than 140/90 on two separate occasions at least one week apart, or medical management for hypertension (i.e. medications including Lisinopril and Diovan). Dyslipidemia is defined by LDL greater than 130 mg/dl, or non-fasting non HDL cholesterol ≥160mg/dL or medical management for dyslipidemia (medications including Niacin, Lovastatin)  Type 2 Diabetes: Individuals will be excluded if they have Type 2 Diabetes Pregnancy: Women who are pregnant or lactating will be excluded from participation Conditions that affect adherence: Participants should not have a condition that would limit participation which medical conditions that would affect individuals' ability to use the computer for prolonged period of time; leave the individual unable to ambulate; or current diagnoses of an eating disorder (anorexia, bulimia,), unmanaged psychiatric disorder (depression, anxiety, attention deficit hyperactivity disorder (ADHD), schizophrenia), or an intellectual impairment that would impact study adherence Abnormal glucose related to medications: Participants should not be taking medications that would limit participation and cause abnormal glucose levels (e.g. atypical antipsychotic medications or glucocorticoids) including diabetic drugs such as Metformin Unwilling or unable to eat study food: Participants who are unwilling or not able to eat the study food (a PowerBar) will not be able to take part in this study. Prior participation in similar studies: Individuals who have recently participated in a laboratory study using similar methods may also be excluded Do not meet discounting Individuals who do not meet discounting (e.g. nonsystematic discounting) on a delay discounting task may be excluded
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Assess Level of High Sensitive CRP in Diabetics and Prediabetics Pre-diabetic patients A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4% Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level >126 mg/dl A 2-hour blood glucose level > 200 mg/dl Hb A1C > 6.5%  Pregnant or lactating females Patients who have recent infection Patients with acute inflammatory diseases as autoimmune diseases Patients with malignancy or on chemotherapy Patients with acute or chronic liver or renal diseases
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 1 Type 1 diabetes 2. Patients who can understand the issue of this study and who are able to decide for themselves whether or not to participate in the study. 3. Adult patient (>18 years old) 4. Informed Consent form signed 5. Differentiated Group A: absence of neuropathy Group B: significant neuropathy  Treatment with beta-blockers 2. Alcohol consumption(> 50 gr/week) 3. Allergy to 18F-FDG 4. Participation in another clinical study (4 weeks prior to entry) that may influence the activity of brown adipose tissue 5. Pregnancy 6. Exposure to ionizing radiation greater than or equal to 5 mSv during the year preceding the PET-RMI planned in the study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 1 Male and female participants of at least 18 years of age Diagnosis of type 1 diabetes mellitus (diagnosed according to World Health Organization criteria) for at least 1 year Availability to wear Freestyle Libre sensor Signature of informed consent  Pregnancy, breastfeeding, intention to undergo pregnancy Known allergies to skin patches or disinfectants used during the study Skin lesions, irritation, redness, edema in sites where sensors can be applied, as this might interfere with sensor's placement Use of drugs that may interfere with glucose metabolism (such as steroids) unless they are chronic therapies whose dosage has remained stable over the past 3 months and is expected to remain stable during the study period Severe medical or psychological conditions, which, in the opinion of the medical team, may compromise patients' safety while using freestyle LIbre sensor Patients enrolled in other clinical trials patients that usually wear other continuous glucose monitoring system
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Acromegaly Muscle Dysfunction Physical Activity Exercise Patients with acromegaly, of both sexes, older than 18 and younger than 65 years, either with active or controlled disease Patients who present clinical stability and who are eligible for the treatment protocol (patients with hormone deficiency will continue on replacement therapy - SILVA et al., 2013) Signature of the Informed Consent Term (TCLE)  Patients with inability to perform the 6MWT, according to ATS criteria Patients who have cognitive impairment by mini mental state examination (MEEN) Abandonment of treatment during the application of the protocol Uncontrolled hypertension (> 180/100 mmHg with medication use) Use of psychotropic drugs Any significant limitations due to osteoarthropathy History of surgery in the previous year with exercise restriction. Não Untreated hypothyroidism or hypocortisolism (HUBBLE et al., 2014) IPAQ with very active classification
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Type1diabetes Males and females with T1D for at least 1 year Age 18 to 30 years Tanner stage ≥ IV BMI 18.5-30 kg/m2 Stable glycemic control (HbA1c 7-9%) Use of a continuous glucose monitor (CGM) Use of an insulin pump Attendance of at least 3 diabetes care visits over the past 12 months  Ketoacidosis or severe hypoglycemia with seizure or coma in the past year Dietary restrictions or intolerances that are incompatible with the planned food deliveries, e.g. celiac disease, gastroparesis, certain food allergies Following a weight-loss or otherwise restrictive diet Use of medications or supplements other than insulin to control blood glucose Vigorous exercise >2 hours on >3 days a week History of an eating disorder or at risk for eating disorder, assessed by the Eating Disorders Diagnostic Scale (EDDS) Major medical illness or use of medications that could interfere with metabolic or glycemic variables Significant psychiatric illness or use of psychotropic medication Smoking, use of recreational drugs, or excessive alcohol consumption Pregnancy or breastfeeding
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Type 1 Diabetes Mellitus Diagnosis of type 1 diabetes Living in the province of Quebec (Canada)  Type 2 diabetes Gestational diabetes
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Type 1 Diabetes Mellitus Criteria:stimulated c peptide <0.03 mmol/l type 1 diabetes -  • Type 2 diabetes Fertile women not using chemical (tablet/pill, depot injection of progesterone, subdermal gestagen implantation, hormonal vaginal ring or transdermal hormonal patch) or mechanical (spirals) contraceptives Pregnant or nursing women Cancer unless in complete remission for > 5 years Treatment with oral glucocorticoids Hypoglycaemia unawareness (unability to register low blood glucose) Known or suspected hypersensitivity to trial product or related products Abuse of alcohol or drugs, or any other co-existing condition that would make patients unsuitable to participate in the study, as deemed by the investigators Receipt of an investigational drug within 30 days prior to visit 0 Simultaneous participation in any other clinical intervention trial